Lechien Jerome R, Saussez Sven
Department of Otolaryngology, Polyclinic of Poitiers, Elsan, Poitiers, France.
Department of Surgery, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.
Otolaryngol Head Neck Surg. 2025 Apr;172(4):1450-1458. doi: 10.1002/ohn.1149. Epub 2025 Jan 31.
To investigate the effectiveness of platelet-rich plasma (PRP) injection into the olfactory clefts of coronavirus disease 2019 (COVID-19) patients with persistent anosmia, hyposmia, and parosmia.
Controlled study.
Multicenter study.
From March 2022 to July 2024, 514 COVID-19 patients undergoing PRP injection and olfactory training versus olfactory training (controls) for a persistent olfactory dysfunction (OD) were consecutively recruited from two medical centers. Subjects were evaluated from pre- to 3 months post-injection with the olfactory disorder questionnaire (ODQ) and the threshold, discrimination, and identification (TDI) test. Olfactory outcomes were compared between controls and patients considering the type of OD (anosmia, hyposmia, and parosmia).
The PRP group was composed of 416 patients with anosmia (N = 111; 26.7%), hyposmia (N = 160; 38.5%), and parosmia (N = 145; 34.9%). The baseline ODQ of patients with parosmia was significantly higher than those of the other groups (P = .001). The increase in TDI subscores and total score was significantly higher in all PRP subgroups compared to controls (P = 0.001). The ODQ significantly reduced from pre- to post-PRP injection in hyposmia and parosmia groups (P = 0.001). Patients with parosmia showed a significantly greater reduction in ODQ scores compared to the control group. The 3-month TDI score was negatively influenced by the age of patients (r = -0.263; P = 0.001) and the duration of OD (r = -0.213; P = .001).
Patients with parosmia experienced a stronger impact of OD on quality of life (QoL), and showed greater QoL improvement following PRP injections compared to other groups.
探讨向患有持续性嗅觉丧失、嗅觉减退和嗅觉异常的2019冠状病毒病（COVID-19）患者的嗅裂内注射富血小板血浆（PRP）的有效性。
对照研究。
多中心研究。
2022年3月至2024年7月，从两个医疗中心连续招募了514名接受PRP注射和嗅觉训练的COVID-19患者以及仅接受嗅觉训练的对照组患者，他们均患有持续性嗅觉功能障碍（OD）。在注射前至注射后3个月期间，使用嗅觉障碍问卷（ODQ）以及阈值、辨别和识别（TDI）测试对受试者进行评估。根据嗅觉功能障碍的类型（嗅觉丧失、嗅觉减退和嗅觉异常）对对照组和患者的嗅觉结果进行比较。
PRP组由416名患者组成，其中嗅觉丧失患者111名（26.7%），嗅觉减退患者160名（38.5%），嗅觉异常患者145名（34.9%）。嗅觉异常患者的基线ODQ显著高于其他组（P = 0.001）。与对照组相比，所有PRP亚组的TDI子分数和总分增加均显著更高（P = 0.001）。嗅觉减退和嗅觉异常组中，从注射PRP前到注射后，ODQ显著降低（P = 0.001）。与对照组相比，嗅觉异常患者的ODQ分数降低幅度显著更大。3个月时的TDI分数受到患者年龄（r = -0.263；P = 0.001）和嗅觉功能障碍持续时间（r = -0.213；P = 0.001）的负面影响。
与其他组相比，嗅觉异常患者的嗅觉功能障碍对生活质量（QoL）的影响更强，并且在接受PRP注射后生活质量改善更大。
